Home
Resources
Publications
CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus

CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus

Sydney R Rooney, Elaine L Shelton, Ida Aka, Christian M Shaffer, Ronald I Clyman, John M Dagle, Kelli Ryckman, Tamorah R Lewis, Jeff Reese, Sara L Van Driest, Prince J Kannankeril

Pharmacogenomics. 2019 Aug;20(13):939-946.

PMID: 31486736

Abstract:

Aims: To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). Patients & Methods: This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. Results: In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and CYP2C9*2 (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. Conclusion: Age, surfactant use, and CYP2C9*2 influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP53861-B	Indomethacin		53-86-1	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: